FDA approves pembrolizumab for adjuvant treatment of Stage IIB or IIC melanoma

[FDA]

On December 3,2021, the Food and Drug Administration approved pembrolizumab (Keytruda, Merck) for the adjuvant treatment of adult and pediatric (≥12 years of age) patients with stage IIB or IIC melanoma following complete resection.


Baca selengkapnya di : http://www.fda.gov...